HC Wainwright Reiterates Buy Rating for GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 229.22% from the company’s previous close.

A number of other research firms also recently weighed in on GOVX. Alliance Global Partners began coverage on shares of GeoVax Labs in a research note on Monday, November 11th. They set a “buy” rating and a $15.00 price target on the stock. Noble Financial lifted their target price on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a research report on Monday, August 19th. Finally, EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, GeoVax Labs presently has a consensus rating of “Buy” and a consensus target price of $13.25.

GeoVax Labs Trading Down 6.9 %

NASDAQ GOVX opened at $2.43 on Friday. GeoVax Labs has a twelve month low of $1.09 and a twelve month high of $11.18. The firm has a 50-day simple moving average of $2.37 and a 200 day simple moving average of $2.61.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The firm had revenue of $2.79 million during the quarter, compared to the consensus estimate of $1.84 million. During the same quarter in the prior year, the business posted ($4.80) EPS. As a group, sell-side analysts expect that GeoVax Labs will post -5.1 earnings per share for the current fiscal year.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.